Elite in Squamous Cell Lung Carcinoma

Morihito Okada

Hiroshima, JP 
Elite in Squamous Cell Lung Carcinoma
Hiroshima, JP 
OverviewLocationsClinical Research

Overview

Morihito Okada practices in Hiroshima, Japan. Okada is rated as an Elite expert by MediFind in the treatment of Squamous Cell Lung Carcinoma. Their top areas of expertise are Lung Adenocarcinoma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mastectomy, and Tissue Biopsy.

Their clinical research consists of co-authoring 530 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 13 articles in the study of Squamous Cell Lung Carcinoma.

Locations

Hiroshima, Japan
Other Locations
Minami, 7348551, Japan
Kyoto, Japan
Horoshima, Japan
Suita, Japan
Yamagata, Japan
St. Luke's International Hospital, Tokyo, Japan
Higashihiroshima, Japan
Nagoya, Japan
Miemachi, Japan
Nagano, 3818551, Japan
Osaka, Japan
Takatsuki, Japan
Towada, Japan
Ube, 7558505, Japan
Tsu, Japan
Niigata, Japan
Kurashiki, Japan
Yamaguchi, Japan
Wakayama, Japan
Nata, Japan
Sakai, 5918555, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 3
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Cisplatin, Carboplatin
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
View 2 Less Clinical Trials

530 Total Publications

Reply to: "Should Muscle Mass be Incorporated into Surgical Decision Making for Early-Stage Lung Cancer?", by Yan et al.
Reply to: "Should Muscle Mass be Incorporated into Surgical Decision Making for Early-Stage Lung Cancer?", by Yan et al.
Journal: Annals of surgical oncology
Published: July 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Okada's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 46 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile